The protective effects of Levilactobacillus brevis FZU0713 on lipid metabolism and intestinal microbiota in hyperlipidemic rats

• Published in: Food science and human wellness Vol. 12; no. 5; pp. 1646 - 1659
• Main Authors: Fan, Xiaoyun, Zhang, Qing, Guo, Weiling, Wu, Qi, Hu, Jinpeng, Cheng, Wenjian, Lü, Xucong, Rao, Pingfan, Ni, Li, Chen, Youting, Chen, Lijiao
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.09.2023; Institute of Food Science and Technology,College of Biological Science and Engineering,Fuzhou University,Fuzhou 350108,China; College of Food Science,Fujian Agriculture and Forestry University,Fuzhou 350002,China%Institute of Food Science and Technology,College of Biological Science and Engineering,Fuzhou University,Fuzhou 350108,China; College of Food Science,Fujian Agriculture and Forestry University,Fuzhou 350002,China; Jinjiang Food Engineering Research Center,School of Advanced Manufacturing,Fuzhou University,Jinjiang 362200,China%College of Food Science,Fujian Agriculture and Forestry University,Fuzhou 350002,China%Institute of Food Science and Technology,College of Biological Science and Engineering,Fuzhou University,Fuzhou 350108,China%Institute of Food Science and Technology,College of Biological Science and Engineering,Fuzhou University,Fuzhou 350108,China; Jinjiang Food Engineering Research Center,School of Advanced Manufacturing,Fuzhou University,Jinjiang 362200,China%Institute of Food Science and Technology,College of Biological Science and Engineering,Fuzhou University,Fuzhou 350108,China; Department of Hepatopancreatobiliary Surgery,Fujian Research Institute of Abdominal Surgery,The First Affiliated Hospital of Fujian Medical University,Fuzhou 350005,China%Department of Hepatopancreatobiliary Surgery,Fujian Research Institute of Abdominal Surgery,The First Affiliated Hospital of Fujian Medical University,Fuzhou 350005,China; Tsinghua University Press
• Subjects: Hyperlipidemia; Intestinal microbiota; Levilactobacillus brevis FZU0713; Lipid metabolism; Liver metabolomics; mRNA expression; Liver metabolomics; Lipid metabolism; Hyperlipidemia; Intestinal microbiota; Levilactobacillus brevis FZU0713; mRNA expression
• ISSN: 2213-4530; 2213-4530
• DOI: 10.1016/j.fshw.2023.02.021

Levilactobacillus brevis FZU0713, a potential probiotic previously isolated from the traditional brewing process of Hongqu rice wine, may have the beneficial effects on improving lipid metabolism. This study aimed to evaluate the in vivo protective effects and possible mechanism of L. brevis FZU0713 on the disturbance of lipid metabolism in hyperlipidemic rats fed a high-fat diet (HFD). Results showed that oral administration of L. brevis FZU0713 could significantly inhibit obesity, ameliorate the lipid metabolism disorder, including serum/liver biochemical parameters and hepatic oxidative stress in HFD-fed rats. Histopathological result also indicated that dietary intervention of L. brevis FZU0713 could reduce the accumulation of lipid droplets in liver induced by 8 weeks HFD feeding. Furthermore, L. brevis FZU0713 intervention significantly increased the fecal levels of short-chain fatty acids (SCFAs, including acetate, propionate, butyrate, isobutyrate, valerate and isovalerate) in HFD-fed rats, which may be closely related to the changes of intestinal microbial composition and metabolic function. Intestinal microbiota profiling by 16S rRNA gene sequencing revealed that L. brevis FZU0713 intervention significantly altered the relative abundance of Coprococcus, Butyricicoccus, Intestinimonas, Lachnospiraceae FCS020 group, Ruminococcaceae_NK4A214 group, Ruminococcaceae_UCG-005 and UCG-014 at genus levels. Based on Spearman's rank correlation coefficient, serum and liver lipid metabolism related biochemical parameters were positively correlated with genera Ruminococcus, Pediococcus and Lachnospiraceae, but negatively correlated with genera Pseudoflavonifractor, Butyricicoccus and Intestinimonas. Furthermore, liver metabolomics analysis demonstrated that L. brevis FZU0713 had a significant regulatory effect on the composition of liver metabolites in hyperlipidemic rats, especially the levels of some important biomarkers involved in the metabolic pathways of arachidonic acid metabolism, primary bile acid biosynthesis, amino sugar and nucleotide sugar metabolism, taurine and hypotaurine metabolism, biosynthesis of unsaturated fatty acid, fructose and mannose metabolism, tyrosine metabolism, etc. Additionally, oral administration of L. brevis FZU0713 significantly regulated the mRNA levels of liver genes (including Acat2, Acox1, Hmgcr, Cd36, Srebp-1c and Cyp7a1) involved in lipid metabolism and bile acid homeostasis. In conclusion, our findings provide the evidence that L. brevis FZU0713 has the potential to improve disturbance of lipid metabolism by regulating intestinal microflora and liver metabonomic profile. Therefore, L. brevis FZU0713 may be used as a potential probiotic strain to produce functional food to prevent hyperlipidemia. [Display omitted] •Levilactobacillus brevisFZU0713 protected against hyperlipidemia.•L. brevisFZU0713 regulated the serum lipid level in rats fed a high-fat diet.•L. brevisFZU0713 increased the abundance of some beneficial intestinal microbial phylotypes.•Liver metabolomics was performed to explore the protective effects of L. brevis FZU0713 on hyperlipidemia.•The hepatic genes involved in lipid metabolism were significantly influenced by L. brevisFZU0713.